Plain-English translation of NCT06095128 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether and —two medications that work in different ways to calm inflammation—are more effective when used together to treat moderate to severe ulcerative colitis. Researchers want to see if this combination can help people whose colitis hasn't responded well to other biologic medications they've tried before. The study will follow participants for up to 76 weeks to measure how well the treatment works.
Many people with severe ulcerative colitis don't respond well enough to current treatments, especially after trying certain biologic medications. This trial is exploring whether using two different medications at the same time might work better for people who have struggled with previous treatments.
You likely qualify if…
You likely don't qualify if…
For the first 8 weeks, you would receive intravenous infusions of one medication at weeks 0, 2, and 6, while taking a tablet form of the other medication twice daily. If your colitis improves by week 8, you would continue with just the intravenous medication alone every 8 weeks through week 46. The entire study lasts about 76 weeks, with follow-up visits to check how you're doing and monitor for any side effects. After your last dose, the research team would check in with you for another 26 weeks for safety monitoring.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States